Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075718 · ClinicalTrials.gov registry record · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
A Phase 2 study of Glaucoma, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 610
- Enrollment target
- 3
- Study locations
NCT07075718: Recruiting Phase 2 study of Glaucoma, sponsored by Glaukos Corporation.
NCT07075718 is a Phase 2 study of Glaucoma that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 610 participants, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (33% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07075718, a Phase 2 study of Glaucoma, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 610 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Primary Outcome
Change from baseline in diurnal IOP in the study eye at 8AM and 10AM at each of Day 11, Week 6, and Month 3 visits
Conditions Studied
Interventions
- PROCEDURE Sham Procedure
- DRUG Gen 2 Travoprost Intracameral Implant
- DRUG Timolol eye drops 0.5%
- OTHER Placebo eye drops
Study Locations (3)
Colorado
- Glaukos Investigative Site - Grand Junction
Oklahoma
- Glaukos Investigative Site - Oklahoma City
Texas
- Glaukos Clinical Site - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2032-03 |
| Phase | Phase 2 |
What NCT07075718 shows while recruiting
NCT07075718 is an interventional study that assigns participants to a tested intervention. The registered 610 participants enrollment target is mid-sized for trials with a published cap, below the 904-participant average among 92 other Glaucoma trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 4 interventions - of which Sham Procedure is the first listed.
NCT07075718 reports a single indexed study location in Colorado, Oklahoma, Texas.
Frequently Asked Questions
What is clinical trial NCT07075718 about?
NCT07075718 is a clinical study titled "Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant". Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
What is the current status of trial NCT07075718?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 610 participants. The study started on 2025-06-12. Estimated completion is 2032-03.
What conditions does trial NCT07075718 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT07075718?
The interventions under investigation include: Sham Procedure (PROCEDURE), Gen 2 Travoprost Intracameral Implant (DRUG), Timolol eye drops 0.5% (DRUG), Placebo eye drops (OTHER).
Who is sponsoring clinical trial NCT07075718?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07075718 being conducted?
This trial has 3 study locations across Colorado, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07075718's enrollment target sits among peer trials
610 11th of 92 higher than 82 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT05838638 · 610 participants · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI